Minomic International Ltd
ABN 14 124 455 081
www.minomic.com

Suite 2, Ground Floor
75 Talavera Rd
Macquarie Park NSW 2113
AUSTRALIA

P: +61 2 9850 4000
F: +61 2 9850 4020

Dear Shareholders,

Welcome to the fourth quarter newsletter.

In the last quarter of 2018 Minomic has made excellent progress advancing the key commercial milestones for MiCheck®. This has included implementing our 'Early Adopter' strategy in the US market which saw our marketing team presenting the MiCheck® test to a range of key urology providers. To date, all feedback has been very positive. In addition, we have continued our engagement with potential licensee companies, including further face-to-face visits with companies in the US, Europe, and China.

1. Commercialisation of the MiCheck® Test

Making the MiCheck® test available for use in the US, the world's largest healthcare market, remains our first priority. As we have discussed in previous updates Minomic is undertaking several parallel strategies to ensure the commercialisation of MiCheck®. Updates on each of these are detailed below:

Prospective Trial

This trial has been completed, including testing, data analysis, and algorithm development. We are currently finalizing papers for publication that will enable Minomic to report the trial results to the broader clinical and patient communities. Publishing papers detailing the successful performance of MiCheck® is a key strategy in raising the awareness of the clinical utility of the test with our clinical and scientific peers. The first paper, detailing the trial design and comparison to existing tests on the market will be submitted in Q1 2019.

MiCheck® Rollout Strategy – USA

Engaging with Clinicians and Potential License Partners
During this quarter Dr. Douglas Campbell and I attended the Prostate Cancer Foundation (PCF) meeting in Carlsbad, US, presenting MiCheck® results to the attendees, including numerous key opinion leaders. Members of the marketing team also attended the Large Urology Group Practice Association meeting the following week. At both meetings, the MiCheck® test was introduced to potential end-users in large urology practices as part of the Early Adopter program described above.

Minomic continues to engage in both face-to-face and video conference meetings with a number of parties interested in licensing the MiCheck® test. We've just attended the JP Morgan Healthcare Conference in San Francisco which is an important opportunity for the company to bring these licensing opportunities to a suitable commercial conclusion. Following this conference, Minomic has scheduled meetings in other locations in the US and China to meet with additional potential licensees. The company is working with its commercialization adviser to ensure these license negotiations can be concluded as soon as possible.

US-based CLIA Lab Rollout
The company is currently finalizing negotiations with a CLIA Certified "High Complexity" lab that will offer the MiCheck® test as a Laboratory Developed Test (LDT) in the US. As we have remarked previously, launching MiCheck® as an LDT will enable Minomic to generate sales revenues and clinical data, with the latter able to support an ultimate FDA registration. Successfully launching MiCheck® as an LDT will greatly strengthen Minomic's negotiation position with potential licensees.

2. Minomic Collaborations

During this quarter an IDEAL Hub Steering Committee meeting was held at Universiy of South Australia with Dr. Yanling Lu attending as our representative. A team visit by the IDEAL Hub Minomic project group was hosted at Macquarie Park and the team provided senior staff at Minomic with an update on their progress.



3. Intellectual Property

The table below gives an update of the patent estate and the stage of development of each family. Notably, a new provisional patent has been submitted to cover MiCheck® algorithm development arising from the Prospective Trial analyses.

Patent Family	Stage of Development
1. Cell Surface Prostate Cancer Antigen for Diagnosis	PCT completed, Registered SG, CN, US National Phase process continuing: AU, CA, EU, HK, JP and KR
2. Monoclonal ANTI-GPC-1 Antibodies and Uses Thereof	PCT completed, National Phase continuing: AU, CN, CA, EU, HK, JP, KR, SG and US
3. Glypican Epitopes and Uses Thereof	PCT completed, National Phase continuing: AU, CN, CA, EU, HK, JP, KR, SG and US
4. Biomarker Combinations for Prostate Disease	PCT completed, National Phase continuing: AU, CN, CA, EU, HK, JP, KR, SG and US
5. Biomarker Combinations for Determining Aggressive Prostate Cancer	Provisional patent lodged

4. Events

J.P. Morgan Health Care Investor Conference was held in San Francisco, California, (7–10 January 2019). This is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

The American Society of Clinical Oncology – Genitourinary Cancers Symposium will take place on 14-16 February 2019 in San Francisco, California. The meeting aims to discover and share ground-breaking research among members of the cancer care and research community who diagnose, treat, and study genitourinary malignancies.

In conclusion, the last quarter of 2018 has ended well and we anticipate exciting developments in 2019.

Yours sincerely,

Dr Bradley Walsh
CEO